NCT03159000

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

Double-Blind, Placebo Controlled Trial of Greater Occipital Nerve Block for the Treatment of Migraine Attacks

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Thomas Jefferson University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Several observational studies have shown improvement in episodic migraine with the use of greater occipital nerve block as an acute therapy, and a recent placebo controlled trial did not show a decrease in frequency of episodic or chronic migraine; however, there has never been a placebo controlled trial to investigate the efficacy of GONB as an acute treatment for headache, and there has been no determination of guidelines for selection of patients who would be most likely to respond to GONB. In light of the above, the investigators propose a double-blind, placebo-controlled, randomized trial examining the use of GONB with lidocaine/bupivocaine in patients with an acute episodic migraine. The results of this trial are expected to guide more appropriate therapeutic management of these participants and the optimal use of this procedure. 50 subjects will be entered into this study. This study is being conducted at Thomas Jefferson University only.

Conditions

• Migraine

Interventions

Type	Name	Description
DRUG	Saline	1ml of 1/3 saline
COMBINATION_PRODUCT	lidocaine/bupivacaine	1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine

Timeline

• Start date: 2017-05-01
• Primary completion: 2017-12-31
• Completion: 2018-06-30
• First posted: 2017-05-18
• Last updated: 2021-11-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study